# CITATION REPORT List of articles citing

Interferon gamma in cancer immunotherapy

DOI: 10.1002/cam4.1700 Cancer Medicine, 2018, 7, 4509-4516.

Source: https://exaly.com/paper-pdf/71263119/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
202	Interferon gamma in cancer immunotherapy. <i>Cancer Medicine</i> , <b>2018</b> , 7, 4509-4516	4.8	142
201	Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors. <b>2019</b> , 36, 2638-2678		86
200	Biomedical Applications of Hyaluronic Acid-Based Nanomaterials in Hyperthermic Cancer Therapy. <b>2019</b> , 11,		18
199	A new strategy for enhancing antitumor immune response using dendritic cells loaded with chemo-resistant cancer stem-like cells in experimental mice model. <b>2019</b> , 111, 106-117		7
198	IFN-IPromotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer. <b>2019</b> , 240, 115-123		26
197	Visualization and quantification of NK cell-mediated cytotoxicity over extended time periods by image cytometry. <b>2019</b> , 469, 47-51		8
196	PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-\( \precede 2019 \), 10, 1903-19	17	9
195	tumor-suppressing and anti-angiogenic activities of a recombinant anti-CD3[hanobody in breast cancer mice model. <b>2019</b> , 11, 1555-1567		6
194	Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN in combination with chemotherapy. <b>2019</b> , 5, FSO435		2
193	STAT1 inhibits T-cell exhaustion and myeloid derived suppressor cell accumulation to promote antitumor immune responses in head and neck squamous cell carcinoma. <b>2020</b> , 146, 1717-1729		23
192	Development of reporter gene assays to determine the bioactivity of biopharmaceuticals. <b>2020</b> , 39, 107	466	12
191	PiggyBac-engineered T cells expressing a glypican-3-specific chimeric antigen receptor show potent activities against hepatocellular carcinoma. <b>2020</b> , 225, 151850		16
190	Roles of IFN-lin tumor progression and regression: a review. <b>2020</b> , 8, 49		108
189	CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer. <b>2020</b> , 495, 12-21		15
188	Searching for the real function of mTOR signaling in the regulation of PD-L1 expression. <b>2020</b> , 13, 10084	.7	10
187	Baseline IFN-land IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients. <b>2020</b> , 10, 17626		3
186	Potential antitumor activity of digitoxin and user-designed analog administered to human lung cancer cells. <b>2020</b> , 1864, 129683		O

## (2020-2020)

185	CD40 Agonist Restores the Antitumor Efficacy of Anti-PD1 Therapy in Muscle-Invasive Bladder Cancer in an IFN I/II-Mediated Manner. <b>2020</b> , 8, 1180-1192	7
184	A Targeted Bioinformatics Assessment of Adrenocortical Carcinoma Reveals Prognostic Implications of GABA System Gene Expression. <b>2020</b> , 21,	3
183	Prognostic Role of Inflammasome Components in Human Colorectal Cancer. <b>2020</b> , 12,	3
182	The Effects of Mesenchymal Stem Cells on Antimelanoma Immunity Depend on the Timing of Their Administration. <b>2020</b> , 2020, 8842659	2
181	Gamma Radiation-Attenuated Provokes Apoptosis in Ehrlich Ascites Carcinoma-Bearing Mice Generating Long-Lasting Immunity. <b>2020</b> , 19, 1533033820926593	5
180	Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment-Current Progress, Strategy, and Future Perspective. <b>2020</b> , 11, 1508	30
179	NKp30 - A prospective target for new cancer immunotherapy strategies. <b>2020</b> , 177, 4563-4580	9
178	Pan-TGFIInhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade. <b>2020</b> , 9, 1811605	6
177	Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review. <b>2020</b> , 21,	10
176	Anticancer Effect of a Spiro-acridine Compound Involves Immunomodulatory and Anti-angiogenic Actions. <b>2020</b> , 40, 5049-5057	2
175	Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma. <b>2020</b> , 59, 102962	18
174	Extracellular Vesicles Derived From Colorectal Cancer Affects CD8 T Cells: An Analysis Based on Body Mass Index. <b>2020</b> , 8, 564648	1
173	-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Restructures the Immune Contexture to Improve Checkpoint Blockade Efficacy. <b>2020</b> , 8,	6
172	Pr⊠isionsmedizin bei NSCLC im Zeitalter der Immuntherapie: Neue Biomarker zur Selektion der am besten geeigneten Therapie oder des am besten geeigneten Patienten. <b>2020</b> , 8, 300-317	
171	Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. <b>2020</b> , 12,	27
170	Novel Variants of and in the Interferon Gamma Signaling Pathway Are Associated with Non-Small Cell Lung Cancer Survival. <b>2020</b> , 29, 1679-1688	1
169	TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival. <b>2020</b> , 12,	12
168	NGS Evaluation of Colorectal Cancer Reveals Interferon Gamma Dependent Expression of Immune Checkpoint Genes and Identification of Novel IFNIInduced Genes. <b>2020</b> , 11, 224	8

167	The interaction between ferroptosis and lipid metabolism in cancer. 2020, 5, 108	75
166	Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges. <b>2020</b> , 12,	16
165	Interferons: role in cancer therapy. <b>2020</b> , 12, 833-855	10
164	Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma. <b>2020</b> , 52, 102647	16
163	Transcriptome meta-analysis reveals differences of immune profile between eutopic endometrium from stage I-II and III-IV endometriosis independently of hormonal milieu. <b>2020</b> , 10, 313	27
162	Assessment of IFNITesponsiveness in patient-derived xenografts. <b>2020</b> , 631, 415-427	1
161	Natural Killer Cell Defects in Breast Cancer: A Key Pathway for Tumor Evasion. <b>2021</b> , 40, 197-216	1
160	Quantitative Systems Pharmacology Modeling of PBMC-Humanized Mouse to Facilitate Preclinical Immuno-oncology Drug Development. <b>2021</b> , 4, 213-225	2
159	Systemic dendrimer delivery of triptolide to tumor-associated macrophages improves anti-tumor efficacy and reduces systemic toxicity in glioblastoma. <b>2021</b> , 329, 434-444	11
158	IFNgamma-inducible CXCL10/CXCR3 axis alters the sensitivity of HEp-2lcells to ionizing radiation. <b>2021</b> , 398, 112382	3
157	Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. <b>2021</b> , 16, 223-249	151
156	A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC. <b>2021</b> , 70, 1667-1678	8
155	Prognostic significance of PD-1/PD-L1 expression in uveal melanoma: correlation with tumor-infiltrating lymphocytes and clinicopathological parameters. <b>2021</b> , 70, 1291-1303	8
154	Using deep learning to predict anti-PD-1 response in melanoma and lung cancer patients from histopathology images. <b>2021</b> , 14, 100921	6
153	Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation. <b>2021</b> , 2021, 6668573	3
152	The Importance of / Assessment in Non-Small Cell Lung Carcinomas. <b>2021</b> , 11,	10
151	High-Density, Targeted Monitoring of Tyrosine Phosphorylation Reveals Activated Signaling Networks in Human Tumors. <b>2021</b> , 81, 2495-2509	14
150	Oxidized-Desialylated Low-Density Lipoprotein Inhibits the Antitumor Functions of Lymphokine Activated Killer Cells. <b>2021</b> , 12, 4993-5004	O

## (2021-2021)

149	Flow cytometry detection of cell type-specific expression of programmed death receptor ligand-1 (PD-L1) in colorectal cancer specimens. <b>2021</b> , 7, e05880	1
148	Next-Generation Immunotherapies to Improve Anticancer Immunity. <b>2020</b> , 11, 566401	2
147	Potential Mechanism of Immune Evasion Associated with the Master Regulator ASCL2 in Microsatellite Stability in Colorectal Cancer. <b>2021</b> , 2021, 5964752	1
146	Immune classification of clear cell renal cell carcinoma. <b>2021</b> , 11, 4338	8
145	A Palette of Cytokines to Measure Anti-Tumor Efficacy of T Cell-Based Therapeutics. <b>2021</b> , 13,	5
144	Strain-Specific Enhances the Efficacy of Cancer Therapeutics in Tumor-Bearing Mice. <b>2021</b> , 13,	8
143	Maternal Serum Cytokine Concentrations in Healthy Pregnancy and Preeclampsia. <b>2021</b> , 2021, 6649608	14
142	Identification and Validation of a Novel Immune-Related Four-lncRNA Signature for Lung Adenocarcinoma. <b>2021</b> , 12, 639254	10
141	Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma. <b>2021</b> , 11, 6276	6
140	Enhanced antitumoral activity of TLR7 agonists via activation of human endogenous retroviruses by HDAC inhibitors. <b>2021</b> , 4, 276	4
139	Immunotherapy and predictive immunologic profile: the tip of the iceberg. 2021, 38, 51	3
138	A novel immunochemotherapy based on targeting of cyclooxygenase and induction of immunogenic cell death. <b>2021</b> , 270, 120708	5
137	Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes. <b>2021</b> , 12, 607282	3
136	Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor. <b>2021</b> , 13,	3
135	Antitumor effects of Auraptene in 4T1 tumor-bearing Balb/c mice. 2021, 42, 245-252	1
134	CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities. <b>2021</b> , 44, 495-523	7
133	Splice-Switching Antisense Oligonucleotides as a Targeted Intrinsic Engineering Tool for Generating Armored Redirected T Cells. <b>2021</b> , 31, 145-154	0
132	A narrative review of tumor-associated macrophages in lung cancer: regulation of macrophage polarization and therapeutic implications. <b>2021</b> , 10, 1889-1916	13

131	Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer. <b>2021</b> , 12, 646874	0
130	Host IL11 Signaling Suppresses CD4 T cell-Mediated Antitumor Responses to Colon Cancer in Mice. <b>2021</b> , 9, 735-747	6
129	Enhanced response to PD-L1 silencing by modulation of TME via balancing glucose metabolism and robust co-delivery of siRNA/Resveratrol with dual-responsive polyplexes. <b>2021</b> , 271, 120711	14
128	Ivacaftor Inhibits Glioblastoma Stem Cell Maintenance and Tumor Progression. <b>2021</b> , 9, 678209	3
127	Cross-species identification of cancer-resistance associated genes uncovers their relevance to human cancer risk.	О
126	Targeting DDX3X Triggers Antitumor Immunity via a dsRNA-Mediated Tumor-Intrinsic Type I Interferon Response. <b>2021</b> , 81, 3607-3620	1
125	Immu-Mela: An open resource for exploring immunotherapy-related multidimensional genomic profiles in melanoma. <b>2021</b> , 48, 361-368	1
124	5-Aminolevulinic acid/sodium ferrous citrate enhanced the antitumor effects of programmed cell death-ligand 1 blockade by regulation of exhausted T cell metabolism in a melanoma model. <b>2021</b> , 112, 2652-2663	2
123	Immunological Effects of Histotripsy for Cancer Therapy. <b>2021</b> , 11, 681629	4
122	CRISPR activation and interference screens in primary human T cells decode cytokine regulation.	1
121	The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer. <b>2021</b> , 6, 100123	5
120	Cancer immunotherapy: itß time to better predict patientsRresponse. <b>2021</b> , 125, 927-938	6
119	Tumor hypoxia-activated combinatorial nanomedicine triggers systemic antitumor immunity to effectively eradicate advanced breast cancer. <b>2021</b> , 273, 120847	15
118	Single-cell RNA sequencing in human lung cancer: Applications, challenges, and pathway towards personalized therapy. <b>2021</b> , 84, 563-576	1
117	Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic Efficacy: A Computational Retrospective Study. <b>2021</b> , 12, 685370	4
116	Interferon-Elteammate or opponent in the tumour microenvironment?. <b>2021</b> ,	33
115	Role of Cytokines and Chemokines in NSCLC Immune Navigation and Proliferation. 2021, 2021, 5563746	6
114	Upregulation of HOXC9 generates interferon-gamma resistance in gastric cancer by inhibiting the DAPK1/RIG1/STAT1 axis. <b>2021</b> , 112, 3455-3468	3

## (2021-2021)

113	Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis. <b>2021</b> , 275, 120988	8
112	Enhancement of interferon gamma stability as an anticancer therapeutic protein against hepatocellular carcinoma upon interaction with calycosin. <b>2021</b> , 185, 813-820	2
111	Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFIPD-L1 blockade-treated squamous cell carcinoma. <b>2021</b> , 4, 1005	2
110	Prognostic value of cytokines in breast cancer: Correlation with positive hormonal status and obesity. <b>2021</b> , 12, 67-73	1
109	Development of a Novel Cytokine Vehicle Using Filamentous Phage Display for Colorectal Cancer Treatment. <b>2021</b> , 10, 2087-2095	1
108	Synthesis of pH-sensitive hyaluronic acid nanogels loaded with paclitaxel and interferon gamma: Characterization and effect on the A549 lung carcinoma cell line. <b>2021</b> , 205, 111845	2
107	Psoralidin exerts anti-tumor, anti-angiogenic, and immunostimulatory activities in 4T1 tumor-bearing balb/c mice. <b>2021</b> ,	3
106	HER2/neu-Based Peptide Vaccination-Pulsed with B-Cell Epitope Induced Efficient Prophylactic and Therapeutic Antitumor Activities in TUBO Breast Cancer Mice Model. <b>2021</b> , 13,	1
105	The SNX-482 peptide from Hysterocrates gigas spider acts as an immunomodulatory molecule activating macrophages. <b>2021</b> , 146, 170648	O
104	Development and Clinical Validation of a Seven-Gene Prognostic Signature Based on Multiple Machine Learning Algorithms in Kidney Cancer. <b>2021</b> , 30, 963689720969176	1
103	Elucidation of the Intersystem Crossing Mechanism in a Helical BODIPY for Low-Dose Photodynamic Therapy. <b>2020</b> , 132, 16248-16255	9
102	Elucidation of the Intersystem Crossing Mechanism in a Helical BODIPY for Low-Dose Photodynamic Therapy. <b>2020</b> , 59, 16114-16121	55
101	Interferons in the Therapy of Severe Coronavirus Infections: A Critical Analysis and Recollection of a Forgotten Therapeutic Regimen with Interferon Beta. <b>2020</b> , 70, 291-297	10
100	High-density, targeted monitoring of tyrosine phosphorylation reveals activated signaling networks in human tumors.	1
99	Immune Classification of Clear Cell Renal Cell Carcinoma.	1
98	Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function. <b>2020</b> , 15, e0243145	3
97	Immunotherapy for synovial sarcoma. <b>2019</b> , 6, 191-200	O
96	A Mathematical Model of Breast Tumor Progression Based on Immune Infiltration. <b>2021</b> , 11,	3

95	Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma. <b>2021</b> , 1	1
94	Interferon ©amma in Health and Disease. <b>2019</b> , 12-16	
93	<del>11111111-</del> <del>112</del> 020, 21-34	
92	Alphavirus-Driven Interferon Gamma (IFNg) Expression Inhibits Tumor Growth in Orthotopic 4T1 Breast Cancer Model. <b>2021</b> , 9,	O
91	Prognostic Impact of Monocyte to Lymphocyte Ratio in Clinical Outcome of Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. <b>2020</b> , 9, e1948	2
90	The NF-[Formula: see text]B Signaling and Wnt/[Formula: see text]-catenin Signaling in MCF-7 Breast Cancer Cells in Response to Bioactive Components from Mushroom. <b>2021</b> , 49, 199-215	1
89	Targeting Tumor Immunosuppressive Microenvironment for the Prevention of Hepatic Cancer: Applications of Traditional Chinese Medicines in Targeted Delivery. <b>2020</b> , 20, 2789-2800	2
88	Restructuring of the Immune Contexture Improves Checkpoint Blockade Efficacy in Murine Lung Cancer.	
87	MLLT6 maintains PD-L1 expression and mediates tumor immune resistance. <b>2020</b> , 21, e50155	1
86	Immunomodulatory Effects of Cyperus rotundus Extract on 7,12 Dimethylbenz[a]anthracene (DMBA) Exposed BALB/c Mice. <b>2020</b> , 27, 46-55	O
85	Novel predication of protein biomarkers in interferon-gamma-stimulated breast cancer cells. <b>2019</b> , 13, 35-43	1
84	The investigation of Pulse-Modulated GSM-900 MHz electromagnetic field effects on the electrochemotherapy mechanisms in vivo. <b>2021</b> , 1-9	
83	CPVL promotes glioma progression via STAT1 pathway inhibition through interactions with the BTK/p300 axis. <b>2021</b> ,	2
82	Vesicular IFN-las a cooperative attacker to enhance anti-cancer effect of 5-fluorouracil via thymidine phosphorylase upregulation and tumor microenvironment normalization. <b>2021</b> , 40, 102501	1
81	Effects of Perioperative Dexmedetomidine on Immunomodulation in Uterine Cancer Surgery: A Randomized, Controlled Trial. <b>2021</b> , 11, 749003	1
80	Immunotherapy for cancer treatment during pregnancy. <b>2021</b> , 22, e550-e561	3
79	Biomarkers for predicting the efficacy of immune checkpoint inhibitors <b>2022</b> , 13, 481-495	1
78	Comprehensive Analysis of Copy Number Variation, Nucleotide Mutation, and Transcription Level of PPAR Pathway-Related Genes in Endometrial Cancer <b>2022</b> , 2022, 5572258	O

#### (2022-2022)

77	IFN-Gamma Expression in the Tumor Microenvironment and CD8-Positive Tumor-Infiltrating Lymphocytes as Prognostic Markers in Urothelial Cancer Patients Receiving Pembrolizumab <b>2022</b> , 14,	О
76	Advances in the drug management of basal cell carcinoma 2022, 1-10	1
75	Interferon-lenhances neocortical synaptic inhibition by promoting membrane association and phosphorylation of GABA receptors in a protein kinase C-dependent manner <b>2022</b> , 101, 153-164	2
74	Bioconjugation strategies and clinical implications of Interferon-bioconjugates <b>2022</b> , 172, 157-157	Ο
73	CRISPR activation and interference screens decode stimulation responses in primary human T cells <b>2022</b> , 375, eabj4008	10
72	Precision Targets for Intercepting the Lethal Progression of Prostate Cancer: Potential Avenues for Personalized Therapy <b>2022</b> , 14,	4
71	Identification of a New Cholesterol-Binding Site within the IFN-IReceptor that is Required for Signal Transduction <b>2022</b> , e2105170	1
70	Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents <b>2022</b> , 10,	2
69	The evolutionary legacy of immune checkpoint inhibitors 2022,	5
68	Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer <b>2022</b> , 11,	1
67	High-Energy Photon Attenuation Properties of Lead-Free and Self-Healing Poly (Vinyl Alcohol) (PVA) Hydrogels: Numerical Determination and Simulation <b>2022</b> , 8,	0
66	Next generation of immune checkpoint molecules in maternal-fetal immunity 2022,	2
65	Identification of a novel anticancer mechanism of Paeoniae Radix extracts based on systematic transcriptome analysis <b>2022</b> , 148, 112748	1
64	Comprehensive Molecular Profiling of Colorectal Cancer With Situs Inversus Totalis by Next-Generation Sequencing <b>2022</b> , 12, 813253	O
63	DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy <b>2022</b> , 14, 50	0
62	Presentation_1.pptx. <b>2020</b> ,	
61	Anticancer activity of chicken cathelicidin peptides against different types of cancer 2022, 1	
60	Construction of an Immune-Autophagy Prognostic Model Based on ssGSEA Immune Scoring Algorithm Analysis and Prognostic Value Exploration of the Immune-Autophagy Gene in Endometrial Carcinoma (EC) Based on Bioinformatics <b>2022</b> , 2022, 7832618	O

59	IFNI nhances ferroptosis by increasing JAK-STAT pathway activation to suppress SLCA711 expression in adrenocortical carcinoma <b>2022</b> , 47,	1
58	Biobehavioral Pathways and Cancer Progression: Insights for Improving Well-Being and Cancer Outcomes <b>2022</b> , 21, 15347354221096081	2
57	The germline factor DDX4 contributes to the chemoresistance of small cell lung cancer cells.	О
56	The Effectiveness of Various Chemotherapeutic Agents in Cancer Treatment.	O
55	Naringenin and cryptotanshinone shift the immune response towards Th1 and modulate T regulatory cells via JAK2/STAT3 pathway in breast cancer. <b>2022</b> , 22,	
54	The Microenvironment of Site-Specific Metastasis. <b>2022</b> , 107-115	
53	Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-derived dendritic cells. <b>2022</b> , 10, e004268	1
52	In Vitro Cytotoxicity and Cytokine Production by Lipid-Substituted Low Molecular Weight Branched PEIs Used for Gene Delivery. <b>2022</b> ,	Ο
51	Evaluation and selection of a lead diabody for interferon-IPET imaging. 2022,	0
50	Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations. <b>2022</b> , 6,	Ο
49	Enhanced drug release from a pH-responsive nanocarrier can augment colon cancer treatment by blocking PD-L1 checkpoint and consuming tumor glucose. <b>2022</b> , 219, 110824	3
48	Infections and Pregnancy: Effects on Maternal and Child Health. 12,	1
47	Lipoteichoic Acid Isolated from Staphylococcus aureus Induced THP-1 Cell Apoptosis through an Autocrine Mechanism of Cytokines and SOCS-1-Mediated Bcl2 Inhibition. <b>2022</b> , 50, 293-300	
46	IFN-dependent tumor-antigen cross-presentation by lymphatic endothelial cells promotes their killing by T cells and inhibits metastasis. <b>2022</b> , 8,	O
45	Intratumoral injection of schwannoma with attenuated Salmonella typhimurium induces antitumor immunity and controls tumor growth. <b>2022</b> , 119,	1
44	CD49b Targeting Inhibits Tumor Growth and Boosts Anti-tumor Immunity. 12,	
43	The Role of Inflammatory Cytokines in the Pathogenesis of Colorectal Carcinoma <b>R</b> ecent Findings and Review. <b>2022</b> , 10, 1670	0
42	Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma. <b>2022</b> , 132,	Ο

41	Immune Checkpoint Inhibitors in Cancer Therapy⊞ow to Overcome Drug Resistance?. <b>2022</b> , 14, 3575	2
40	The IFN-Felated long non-coding RNA signature predicts prognosis and indicates immune microenvironment infiltration in uterine corpus endometrial carcinoma. 12,	
39	Advances in Management and Therapeutics of Cutaneous Basal Cell Carcinoma. 2022, 14, 3720	О
38	Immune Biomarkers in Blood from Sarcoma Patients: A Pilot Study. <b>2022</b> , 29, 5585-5603	
37	Lipid metabolism in ferroptosis and ferroptosis-based cancer therapy. 12,	0
36	Cross-species identification of cancer resistancellssociated genes that may mediate human cancer risk. <b>2022</b> , 8,	1
35	Single cell transcriptomic analysis of the immune cell compartment in the human small intestine and in Celiac disease. <b>2022</b> , 13,	1
34	Stability-indicative and conformation-specific enzyme linked immunosorbent assay for analysis of recombinant human gamma interferon. <b>2023</b> , 222, 115070	O
33	Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds. 12,	О
32	The past, present, and future of immunotherapy for bladder tumors. <b>2022</b> , 39,	O
31	Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy. <b>2022</b> , 10, e005320	1
30	Multi-perspective comparison of the immune microenvironment of primary colorectal cancer and liver metastases. <b>2022</b> , 20,	O
29	Patient-Specific Mathematical Model of the Clear Cell Renal Cell Carcinoma Microenvironment. <b>2022</b> , 12, 1681	Ο
28		0
	2022, 12, 1681  DLX2 Is a Potential Immune-Related Prognostic Indicator Associated with Remodeling of Tumor Microenvironment in Lung Squamous Cell Carcinoma: An Integrated Bioinformatical Analysis. 2022,	
28	2022, 12, 1681  DLX2 Is a Potential Immune-Related Prognostic Indicator Associated with Remodeling of Tumor Microenvironment in Lung Squamous Cell Carcinoma: An Integrated Bioinformatical Analysis. 2022, 2022, 1-12	0
28	DLX2 Is a Potential Immune-Related Prognostic Indicator Associated with Remodeling of Tumor Microenvironment in Lung Squamous Cell Carcinoma: An Integrated Bioinformatical Analysis. 2022, 2022, 1-12  Natural killer cell immunotherapy in glioblastoma. 2022, 13,	0

23	Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells. <b>2022</b> ,	0
22	The long multi-epitope peptide vaccine combined with adjuvants improved the therapeutic effects in a glioblastoma mouse model. 13,	Ο
21	Combination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy. <b>2022</b> , 14, 6091	O
20	Controlling Nutritional Status (CONUT) as a Novel Postoperative Prognostic Marker in Breast Cancer Patients: A Retrospective Study. <b>2022</b> , 2022, 1-23	O
19	Boolean modeling reveals that cyclic attractors in macrophage polarization serve as reservoirs of states to balance external perturbations from the tumor microenvironment. 13,	O
18	Interferon gamma-related gene signature based on anti-tumor immunity predicts glioma patient prognosis. 13,	1
17	TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy. <b>2023</b> , 6,	O
16	The germline factor DDX4 contributes to the chemoresistance of small cell lung cancer cells. <b>2023</b> , 6,	O
15	IFNIsignaling in cytotoxic T cells restricts anti-tumor responses by inhibiting the maintenance and diversity of Intra-tumoral stem-like T cells. <b>2023</b> , 14,	O
14	Targeted Cytokine Delivery for Cancer Treatment: Engineering and Biological Effects. <b>2023</b> , 15, 336	O
13	Tumor immunology. <b>2023</b> , 245-452	O
12	The function of guanylate binding protein 3 (GBP3) in human cancers by pan-cancer bioinformatics. <b>2023</b> , 20, 9511-9529	O
11	CAR T-cell therapy: Reprogramming patient immune cell to treat cancer. 2023, 105, 110638	0
10	Macrophage and monocyte subsets as new therapeutic targets in cancer immunotherapy. <b>2023</b> , 8, 100776	Ο
9	Crosstalk of Inflammatory Cytokines within the Breast Tumor Microenvironment. 2023, 24, 4002	0
8	Tumor Evasion of the Immune System: Role of Interferon and Tumor Necrosis Factor in Cancer. <b>2022</b> , 1-27	O
7	Mechanisms of cancer cell death induction by triptolide.	O
6	A survival model for prognostic prediction based on ferroptosis-associated genes and the association with immune infiltration in lung squamous cell carcinoma. <b>2023</b> , 18, e0282888	Ο

#### CITATION REPORT

5	Breast cancer cell growth arrest and chemopreventive effects of Passiflora edulis Sims (Passifloraceae) ethanolic leaves extract on a rat model of mammary carcinoma. <b>2023</b> , 311, 116408	O
4	Oncolytic Adenoviruses Armed with Co-Stimulatory Molecules for Cancer Treatment. <b>2023</b> , 15, 1947	O
3	Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancer.	О
2	Intersections between innate immune response and gastric cancer development. 29, 2222-2240	O
1	Hematopoietic Transfer of the Anti-Cancer and Lifespan-Extending Capabilities of A Genetically Engineered Blood System.	O